244 related articles for article (PubMed ID: 8806975)
1. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists.
Zannad F; Matzinger A; Larché J
Am J Hypertens; 1996 Jul; 9(7):633-43. PubMed ID: 8806975
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
Song JC; White CM
Clin Pharmacokinet; 2002; 41(3):207-24. PubMed ID: 11929321
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study.
Lefebvre J; Poirier L; Archambault F; Jewell D; Reed CV; Lacourcière Y
Can J Cardiol; 1998 May; 14(5):682-8. PubMed ID: 9627524
[TBL] [Abstract][Full Text] [Related]
4. Trough:peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors.
Salvetti A; Di Venanzio L; Arrighi P; Arzilli F
J Hypertens Suppl; 1994 Nov; 12(8):S91-4; discussion S94-5. PubMed ID: 7707164
[TBL] [Abstract][Full Text] [Related]
5. Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors?
Zannad F
Drugs; 1993; 46 Suppl 2():172-81; discussion 182. PubMed ID: 7512472
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of vasodilators. Part I.
Kirsten R; Nelson K; Kirsten D; Heintz B
Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
[TBL] [Abstract][Full Text] [Related]
7. Lisinopril versus enalapril: evaluation of trough:peak ratio by ambulatory blood pressure monitoring.
Diamant M; Vincent HH
J Hum Hypertens; 1999 Jun; 13(6):405-12. PubMed ID: 10408591
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme inhibitors and moderate hypertension.
McAreavey D; Robertson JI
Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.
Messerli FH; Oparil S; Feng Z
Am J Cardiol; 2000 Dec; 86(11):1182-7. PubMed ID: 11090788
[TBL] [Abstract][Full Text] [Related]
10. Urinary kallikrein excretion and blood pressure response to angiotensin converting enzyme inhibitors and calcium antagonists in hypertensive patients.
Dessì-Fulgheri P; Espinosa E; Zingaretti O; Guazzarotti F; Sarzani R; Pupita G; Sturbini S; Catalini R; Rappelli A
J Hypertens; 1993 Jul; 11(7):725-30. PubMed ID: 8228191
[TBL] [Abstract][Full Text] [Related]
11. Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. Italian Nifedipine GITS Study Group.
Zanchetti A
J Hypertens Suppl; 1994 Nov; 12(8):S97-106. PubMed ID: 7707165
[TBL] [Abstract][Full Text] [Related]
12. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
Muijsers RB; Curran MP; Perry CM
Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112
[TBL] [Abstract][Full Text] [Related]
13. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
Lüscher TF; Wenzel RR; Moreau P; Takase H
Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
[TBL] [Abstract][Full Text] [Related]
14. [One-year persistence of fixed-dose combinations of angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertensive patients].
Simonyi G; Ferenci T; Finta E; Igaz I; Balogh S; Gasparics R; Medvegy M
Orv Hetil; 2019 Mar; 160(9):343-348. PubMed ID: 30798621
[TBL] [Abstract][Full Text] [Related]
15. Choosing the right ACE inhibitor. A guide to selection.
Leonetti G; Cuspidi C
Drugs; 1995 Apr; 49(4):516-35. PubMed ID: 7789286
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetic and clinical profiles of angiotensin-converting enzyme inhibitors and calcium antagonists in systemic hypertension.
Frishman WH
Am J Cardiol; 1992 Apr; 69(10):17C-25C. PubMed ID: 1546635
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of high through-to-peak ratio of perindopril in SHR.
Moriyama S; Ishigai Y; Mori T; Fukuzawa A; Shibano T
Clin Exp Hypertens; 1999 Oct; 21(7):1223-38. PubMed ID: 10513838
[TBL] [Abstract][Full Text] [Related]
18. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
19. Overview of the angiotensin-converting-enzyme inhibitors.
Piepho RW
Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S3-7. PubMed ID: 11030016
[TBL] [Abstract][Full Text] [Related]
20. Duration of action of angiotensin converting enzyme inhibitors.
Zannad F
Am J Hypertens; 1995 Oct; 8(10 Pt 2):75S-81S. PubMed ID: 8845089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
